Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (121-130 of 437) with videos related to

Pageof 44
Sort By:
Clinical Epigenetics|November 14, 2019
Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancyDörte Nitschkowski, Sebastian Marwitz, Sousana A Kotanidou, et al.
Clinical Lung Cancer|November 25, 2021
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialJohn V Heymach, Tetsuya Mitsudomi, David Harpole, et al.
Clinical Epigenetics|December 7, 2017
Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expressionSebastian Marwitz, Lena Heinbockel, Swetlana Scheufele, et al.
Cancer Treatment and Research Communications|March 1, 2025
Effectiveness and safety of Atezolizumab in patients with locally-advanced or metastatic non-small cell lung cancer after prior chemotherapy under real-life conditions in Germany: The Non-interventional Study HYPERIONNiels Reinmuth, Christian Geßner, Thomas Schichtl, et al.
International Journal of Cancer|July 6, 2018
Fountain of youth for squamous cell carcinomas? On the epigenetic age of non-small cell lung cancer and corresponding tumor-free lung tissuesSebastian Marwitz, Lena Heinbockel, Swetlana Scheufele, et al.
Targeted Oncology|September 20, 2019
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current StatePetros Grivas, Bradley J Monk, Daniel Petrylak, et al.
European Journal of Cancer (Oxford, England : 1990)|October 8, 2024
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumabMartin Reck, Ana Laura Ortega Granados, Filippo de Marinis, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancerDavid F Heigener, Joachim von Pawel, Corinna Eschbach, et al.
Lung Cancer (Amsterdam, Netherlands)|November 19, 2022
NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapyArne Trummer, Andre Bethge, Nicolas Dickgreber, et al.
British Journal of Cancer|April 29, 2023
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinomaArlou Kristina Angeles, Florian Janke, Ann-Kathrin Daum, et al.
Pageof 44

Showing results (121-130 of 437) with videos related to

Sort By:
Pageof 44
Clinical Epigenetics|November 14, 2019
Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancyDörte Nitschkowski, Sebastian Marwitz, Sousana A Kotanidou, et al.
Clinical Lung Cancer|November 25, 2021
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialJohn V Heymach, Tetsuya Mitsudomi, David Harpole, et al.
Clinical Epigenetics|December 7, 2017
Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expressionSebastian Marwitz, Lena Heinbockel, Swetlana Scheufele, et al.
Cancer Treatment and Research Communications|March 1, 2025
Effectiveness and safety of Atezolizumab in patients with locally-advanced or metastatic non-small cell lung cancer after prior chemotherapy under real-life conditions in Germany: The Non-interventional Study HYPERIONNiels Reinmuth, Christian Geßner, Thomas Schichtl, et al.
International Journal of Cancer|July 6, 2018
Fountain of youth for squamous cell carcinomas? On the epigenetic age of non-small cell lung cancer and corresponding tumor-free lung tissuesSebastian Marwitz, Lena Heinbockel, Swetlana Scheufele, et al.
Targeted Oncology|September 20, 2019
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current StatePetros Grivas, Bradley J Monk, Daniel Petrylak, et al.
European Journal of Cancer (Oxford, England : 1990)|October 8, 2024
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumabMartin Reck, Ana Laura Ortega Granados, Filippo de Marinis, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancerDavid F Heigener, Joachim von Pawel, Corinna Eschbach, et al.
Lung Cancer (Amsterdam, Netherlands)|November 19, 2022
NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapyArne Trummer, Andre Bethge, Nicolas Dickgreber, et al.
British Journal of Cancer|April 29, 2023
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinomaArlou Kristina Angeles, Florian Janke, Ann-Kathrin Daum, et al.
Pageof 44